Liege, Belgium, 14 February 2022 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 442,191 new shares today for a total amount of EUR 8,061,142 following the Put Option Notice issued on 20 December, 2021 in the framework of LDA capital commitment agreement.
As a reminder, LDA Capital commits an amount of up to EUR 50 million in cash within a maximum of three years in exchange for new ordinary shares in Mithra. This is the third put option notice related to this agreement. Following this capital increase’s completion, Mithra now has 44,493,450 outstanding shares carrying voting rights (44,051,259 outstanding shares carrying voting rights previously).
Therefore, Mithra publishes the following updated information:
- Capital: EUR 32,573,434.4
- Total number of securities carrying voting rights: 44,493,450 (all ordinary shares)
- Total number of voting rights (= denominator): 44,493,450 (all relating to ordinary shares)
- Number of outstanding rights to subscribe to securities carrying voting rights:
- Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights giving right to 1,394,900ordinary shares
- Pursuant to the share option plan of 22 July 2020 : 690,000 subscription rights giving right to 690,000 ordinary shares
- Pursuant to the share option plan granted to the lending shareholders of 7 September 2020: 300,000 subscription rights giving right to 300,000 ordinary shares
- Pursuant to the share option plan of 20 November 2020: 74,717 subscription rights giving rise to 74,717 ordinary shares.